Renal Nerve Stimulation in Uncontrolled Hypertensive Patients Undergoing Renal Denervation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-24

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study design: Investigator initiated, single center The study is aimed

1\) To investigate the blood pressure (BP) change to renal nerve stimulation(RNS), and subsequently perform a renal denervation(RDN) procedure

1\) to verify the cutoff value (RNS-induced systolic BP change \<20 mmHg in post-RDN patients) could be a useful clinical endpoint in RDN therapy, and test the hypothesis that intense RDN could improve the efficacy of RDN.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Angiotensinogen Gene and Hypertension

NCT00173004

Hypertension

UNKNOWN

Post-Marketing Follow-Up of Long-term Type Ureteral Stent Set

NCT04250090

Ureter Stricture Hydronephrosis

UNKNOWN

Heart Rate Variability Assessment in Dialysis Patients by Acupuncture

NCT04356794

RLS

COMPLETED NA

Heart Rate Variability in Chronic Kidney Disease Patients

NCT00824577

Chronic Kidney Disease Heart Rate Variability

UNKNOWN

Study of Cryotherapy for Renal Tumors

NCT00858975

Renal Tumors

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypertension has become a global public health concern and associated with considerable risk of cardiovascular, cerebrovascular and kidney diseases. Although pharmacological blood pressure (BP) control can reduce these risks, BP control rates remain suboptimal. Resistant hypertension affects 10% to 15% of patients with hypertension and adequate BP control is associated with better clinical outcome of resistant hypertension. Percutaneous renal denervation system (RDN) is designed to disrupt renal afferent and efferent sympathetic nerves to modulate central sympathetic outflow and renal physiology, achieving sustained BP reduction. Although the randomized, sham-controlled trial, SYMPLICITY HTN-3 in 2014, failed to prove the effectiveness of RDN in reducing BP compared to sham procedure, three carefully designed, randomized sham-controlled RDN trials (SPYRAL HTN-OFF MED, SPYRAL HTN-ON MED, and RADIANCE-HTN SOLO), all of which showed similar and clinically meaningful BP reductions without serious adverse events. RDN, therefore, has been approved and well utilized in clinical practice to treat resistant hypertension. However,15-30% of the patients are non-responders. The reason for this is unknown. Experimental data show that renal nerve stimulation (RNS) may serve as a functional endpoint to assess completeness of the RDN procedure. Our preliminary observation study showed low RNS-induced SBP change in post-RDN patients were associated with better BP lowering response.

Our study objectives are

1\) to investigate the BP change to RNS, and subsequently perform a RDN procedure

1\) to verify the cutoff value (RNS-induced systolic BP change \<20mmHg in post-RDN patients) could be a useful clinical endpoint in RDN therapy.

Hypotheses:

We hypothesize that an RNS-induced SBP increase of \<20 mmHg in bilateral proximal main renal arteries immediately after RDN was associated with significant BP reductions 6 months following RDN. RNS-induced SBP changes could predict RDN response and even guide RDN strategies

Study design: Investigator initiated, single center, prospective study Patient population: 60 patients (20 - 80 years old) Patients with HTN.

1\) 24-hour ambulatory blood pressure monitoring (ABPM) was \>130 or DBP \>80 mmHg

Exclusion criteria:

1. Unsuitable renal artery anatomy (main renal artery lumen diameter ≤3 mm or a total length \<20 mm of the main arteries).
2. Secondary hypertension, including hyperaldosteronism, pheochromocytoma, renal artery stenosis(\>50% stenosis in one or both arteries)
3. Pregnancy

Intervention:

RNS-guided RDN will be performed

1. Group A (N=35): RNS-induced SBP increase of \<20 mmHg in bilateral proximal main renal arteries immediately after RDN
2. Group B(N=25): RNS-induced SBP increase of \>20 mmHg in bilateral proximal main renal arteries immediately after RDN Then we will further divided Group B into Group C (N=8): observation group Group D(N=17): intensive intervention group (intensive -RDN again and the goal was post RNS-induced SBP change \<20 mmHg)

Primary end-points:

The primary end points were the low RNS-induced systolic BP changes after RDN, was associated with the lower 24-hour SBP.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

RNS checked RDN

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

RNS guided RDN

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low RNS-induced SBP change group

25 patients with the RNS-induced systolic BP change \<20mmHg immediately after RDN

Group Type ACTIVE_COMPARATOR

nerve stimulation guided renal denervation procedure

Intervention Type PROCEDURE

RNS-in

High RNS-induced SBP change group

8 patients with the RNS-induced systolic BP change \>20mmHg immediately after RDN

Group Type PLACEBO_COMPARATOR

nerve stimulation guided renal denervation procedure

Intervention Type PROCEDURE

RNS-in

intensive RDN group

17 patients with the initial RNS-induced systolic BP change \>20mmHg immediately after RDN, received intensive RDN therapy and let the second RNS-induced systolic BP change \< 20mmHg

Group Type EXPERIMENTAL

nerve stimulation guided renal denervation procedure

Intervention Type PROCEDURE

RNS-in

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nerve stimulation guided renal denervation procedure

RNS-in

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RNS-guided RDN

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with hypertension (HTN), including

1. 24-hour ambulatory blood pressure \>130/ 80 mmHg
2. Age 20-80 years
3. Glomerular filtration rate \>45 mL/min

Exclusion Criteria

1. Unsuitable renal artery anatomy computed tomographic angiography (main renal artery lumen diameter ≤3 mm or a total length \<20 mm of the main arteries).
2. untreated secondary HTN, including hyperaldosteronism, pheochromocytoma, renal artery stenosis(\>50% stenosis)

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No